What makes orforglipron different from semaglutide?

Orforglipron is a non-peptide small molecule that is orally bioavailable, so it can be taken as a once-daily pill without the strict fasting and water rules required by oral peptide GLP-1 drugs, whereas semaglutide is a peptide usually injected.

Is orforglipron FDA approved?

As of this writing it is in late-stage clinical development rather than fully approved; it has shown strong phase 2 and ongoing phase 3 results for weight loss and diabetes.

How does it cause weight loss?

By activating GLP-1 receptors it reduces appetite, slows gastric emptying, and improves insulin response, leading to reduced caloric intake and weight reduction in trials.

← All peptides

Weight & Metabolic

Clinical

Orforglipron

Also known as: Orforglipron

Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist in late-stage clinical development for obesity and type 2 diabetes. It is studied for weight loss and glycemic control without injections.

Mechanism of Action

Orforglipron is a small-molecule, non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor that, unlike peptide GLP-1 drugs, is orally bioavailable and not degraded in the gut. Activation of the GLP-1 receptor stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. Centrally, GLP-1 receptor signaling in the hypothalamus and brainstem reduces appetite and food intake, driving weight loss. Its small-molecule structure allows once-daily oral dosing without the food and water restrictions of peptide-based oral semaglutide.

Half-life: Long enough to support once-daily oral dosing, roughly in the range of a day
Administration Routes: oral
Research Status: Clinical